Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

Low Stock Prices, High Yields Fuel This Fund's Market Beat

True to its name, DWS CROCI Equity Dividend Fund makes good use of dividend stocks. The fund's trailing 12-month yield was 2.45%, going into Tuesday.

Investors Business Daily

Australia’s booster doses explained: how to decide if you should get a fourth Covid vaccine and how long to wait

How long should I wait after a third dose? Should I wait for an Omicron-specific vaccine? Your questions answered

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Biotechs with $1 Billion in Cash

Worried about a recession? These cashed-up biotech stocks aren't sweating it.

The Street

COVID-19 boosters 'a matter of urgency' says Prime Minister as infections rise to highest level since February

Australia is expected to follow other parts of the world in expanding eligibility for a fourth COVID-19 vaccine dose to the wider population, with the Prime Minister saying the pandemic "isn't over" while encouraging eligible Australians to get their booster shots.

ABC News

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot

Pfizer stock crashed into its 50-day line Tuesday after Germany's CureVac sued its Covid vaccine partner, BioNTech, for patent infringement.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Benzinga

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

Tribune News Service

As Covid Cases Decline, is it Time to Drop Pfizer?

Leading drug maker Pfizer (PFE) experienced robust growth over the past year primarily based on the growing demand for its Covid vaccine. However, as Covid cases decline, will the company be able to maintain its growth trajectory? Let’s find out.

StockNews.com

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

The Guardian - UK

FDA says COVID boosters for the fall must target newer omicron types

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

WEKU

Why Pfizer Stock Is Rising Today

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to fla

Investors Business Daily

The FDA Just Handed BioNTech And Moderna A Gift — But Only One Jumped

The FDA requested vaccine makers update their Covid shots to include an omicron-fighting element on Thursday, and BNTX stock surged.

The Independent UK

Tweaked COVID boosters in US must target newer omicron types

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

The Street

Pfizer Stock Jumps On $3.2 Billion U.S. Covid Vaccine Sale, FDA Paxlovid Approval Filing

“As the Covid pandemic continues to evolve and be highly unpredictable, we must remain vigilant in protecting those who are at greatest risk of getting very sick from Covid," said CEO Albert Bourla.

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 18 strange trades.

The Independent UK

Elmo, 3, joins youngest Americans in getting vaccinated

Elmo got a COVID-19 vaccine

Benzinga

Efficacy Of Pfizer's Paxlovid COVID Drug Crashes, According To New NIH-Funded Study

A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.

Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Revive Therapeutics Data Access Plan Approved By The FDA; Partial Unblinded Data In Company Hands

Revive Therapeutics Ltd. (OTC: RVVTF) moved closer towards potential endpoint change in their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

1 … 42 43 44 45

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.